Sanofi Consumer Healthcare India Ltd (NSE: SANOFICONR) and Sun Pharma Advanced Research Company Limited (Sparc) (NSE: SPARC) are both listed in the Pharmaceuticals industry. Sanofi Consumer Healthcare India has a market capitalisation of ₹8,107 Cr and Sun Pharma Advanced Research Company ₹5,682 Cr, as of 9 Nov 2026. Their P/E ratios are 33.8 and 3.7 respectively. Return on equity is 73.09% for Sanofi Consumer Healthcare India and 2.77% for Sun Pharma Advanced Research Company. Over one year, Sanofi Consumer Healthcare India's share price is down 28.0% and Sun Pharma Advanced Research Company's is up 50.4%.
| Metric | Sanofi Consumer Healthcare India | Sun Pharma Advanced Research Company |
|---|---|---|
| NSE Symbol | SANOFICONR | SPARC |
| BSE Code | 544250 | 532872 |
| Share Price | ₹3,445.00 | ₹210.80 |
| Market Cap | ₹8,107 Cr | ₹5,682 Cr |
| P/E Ratio | 33.8 | 3.7 |
| Return on Equity | 73.09% | 2.77% |
| Return on Assets | 37.99% | 79.74% |
| Dividend Yield | 2.13% | — |
| Beta (1Y) | 0.27 | 0.97 |
| 1-Year Price Change | -28.0% | +50.4% |
| 3-Month Price Change | -23.5% | +1.6% |
| 52-Week Range | ₹3,168.20 – ₹5,255.00 | ₹108.00 – ₹289.00 |
| Latest Quarter | Q2 FY27 | Q2 FY27 |
| Quarterly Revenue | ₹263 Cr | ₹30 Cr |
| Quarterly Net Profit | ₹77 Cr | ₹-24 Cr |
| Net Margin | 29.1% | -81.2% |
| EPS (Basic, Quarter) | ₹33.26 | ₹-0.75 |
| Results Basis | standalone | consolidated |
| Headquarters | Mumbai, Maharashtra | Mumbai, Maharashtra |
The figures sit side by side and are not ranked. Quarterly figures are in ₹ crore, parsed from each company's exchange filing (XBRL); the two companies' latest quarters can differ.
Sanofi Consumer Healthcare India Limited operates as a fast-moving consumer healthcare company in India. It offers products in the allergy, physical wellness, and pain care segments under brands, such as Allegra, Combiflam, Avil, DePURA, Festal, and Novalgin NU through distributors, wholesalers, government institutions and hospitals, pharmacies, pharmacy chains, and e-commerce. The company was incorporated in 2023 and is based in Mumbai, India. Sanofi Consumer Healthcare India Limited is a subsidiary of Opella Healthcare Participations B.V.
Sun Pharma Advanced Research Company Limited, a clinical-stage biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally. It develops products with a therapeutic focus on oncology and immunology. The company is also developing Vodobatinib (SCO-088), a BCR-ABL inhibitor, for the treatment of refractory chronic myelogenous leukemia that is in phase 2 clinical trial; and Vibozilimod (SCD-044), a selective sphingosine-1-phosphate receptor 1 (S1PR1) agonist, for the treatment of psoriasis and atopic dermatitis that is in phase 2 clini…
Sanofi Consumer Healthcare India has a market capitalisation of ₹8,107 Cr, against ₹5,682 Cr for Sun Pharma Advanced Research Company as of 9 Nov 2026, about 1.4 times the size by market cap.
Sanofi Consumer Healthcare India has a P/E of 33.8 and Sun Pharma Advanced Research Company a P/E of 3.7 as of 9 Nov 2026.
Sanofi Consumer Healthcare India has a return on equity of 73.09% and Sun Pharma Advanced Research Company 2.77%.
Sanofi Consumer Healthcare India's share price is down 28.0% over one year and Sun Pharma Advanced Research Company's is up 50.4%.
Sanofi Consumer Healthcare India reported revenue of ₹263 Cr and net profit of ₹77 Cr for Q2 FY27. Sun Pharma Advanced Research Company reported revenue of ₹30 Cr and net profit of ₹-24 Cr for Q2 FY27. Figures are parsed from each company's exchange filing.
Both are classified under Pharmaceuticals > Biotechnology and Life Sciences > Pharmaceuticals on FinBizNet.
No. The page lays the two companies' published figures side by side and draws no conclusion from them. It is descriptive market data, not investment advice.
Data as of 9 Nov 2026. Descriptive market data only — not investment advice.